EBS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Emergent BioSolutions Inc (EBS) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks significant positive catalysts, has weak financial performance, and no strong trading signals. It is better to hold off on investing in EBS until there are clearer signs of improvement in financials or stronger trading signals.
The MACD is positive but contracting, indicating weakening bullish momentum. RSI is neutral at 61.868, showing no overbought or oversold conditions. Moving averages are converging, suggesting a lack of a strong trend. The stock is trading near its pivot point of 8.299, with key resistance at 8.719 and support at 7.878.
Gross margin increased by 8.94% YoY, showing some operational efficiency improvements. Analysts maintain a Buy rating despite lowering the price target.
Net income remains negative at -$54.6M, and EPS is still in the negative territory at -1.
No recent news or significant insider/hedge fund activity. Analysts lowered the price target from $15 to $12, reflecting reduced expectations.
In Q4 2025, revenue declined significantly by 23.63% YoY. However, net income and EPS showed improvement YoY but remain negative. Gross margin increased to 42.91%, indicating some operational improvements.
H.C. Wainwright lowered the price target from $15 to $12 while maintaining a Buy rating, citing reduced earnings expectations after an earnings miss.
